A2 Biotherapeutics

A2 Biotherapeutics is a startup founded in 2016 based in the United States. Its most recent tracked round is Series C+. Brouky classifies it under Software & Developer Tools. Brouky records 3 investors associated with the company.

A2 Biotherapeutics develops precision cell therapies using its Tmod™ platform to selectively target and destroy tumor cells while sparing normal cells, addressing the challenge of distinguishing tumor cells from healthy ones in solid tumor cancers.